

# Nick Scott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6803965/publications.pdf>

Version: 2024-02-01

74  
papers

2,790  
citations

236925

25  
h-index

206112

48  
g-index

81  
all docs

81  
docs citations

81  
times ranked

3266  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX). <i>International Journal of Epidemiology</i> , 2022, 51, e123-e130.	1.9	14
2	Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 18, 100316.	2.9	4
3	The EASL "Lancet Liver Commission; protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	13.7	257
4	Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol. <i>BMJ Open</i> , 2022, 12, e056120.	1.9	0
5	Preventing a cluster from becoming a new wave in settings with zero community COVID-19 cases. <i>BMC Infectious Diseases</i> , 2022, 22, 232.	2.9	9
6	Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020. <i>International Journal of Drug Policy</i> , 2022, 103, 103655.	3.3	8
7	Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019. <i>Epidemiology and Infection</i> , 2022, 150, e7.	2.1	1
8	Prevalence and correlates of simultaneous, multiple substance injection (co-injection) among people who inject drugs in Melbourne, Australia. <i>Addiction</i> , 2021, 116, 876-888.	3.3	10
9	A global investment framework for the elimination of hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 535-549.	3.7	51
10	Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model. <i>International Journal of Drug Policy</i> , 2021, 88, 102634.	3.3	11
11	Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2270-2274.	2.8	3
12	Role of masks, testing and contact tracing in preventing COVID-19 resurgences: a case study from New South Wales, Australia. <i>BMJ Open</i> , 2021, 11, e045941.	1.9	18
13	Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100129.	2.9	6
14	Covasim: An agent-based model of COVID-19 dynamics and interventions. <i>PLoS Computational Biology</i> , 2021, 17, e1009149.	3.2	330
15	The COVID-19 crisis will exacerbate maternal and child undernutrition and child mortality in low- and middle-income countries. <i>Nature Food</i> , 2021, 2, 476-484.	14.0	117
16	A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison. <i>International Journal of Drug Policy</i> , 2021, 94, 103203.	3.3	8
17	A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1624-1634.	2.0	2
18	The Prison and Transition Health (PATH) cohort study: Prevalence of health, social, and crime characteristics after release from prison for men reporting a history of injecting drug use in Victoria, Australia. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108970.	3.2	12

#	ARTICLE	IF	CITATIONS
19	Modelling the impact of relaxing <scp>COVID</scp> â€19 control measures during a period of low viral transmission. Medical Journal of Australia, 2021, 214, 79-83.	1.7	58
20	Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. PLoS Medicine, 2021, 18, e1003818.	8.4	8
21	Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. Clinical Infectious Diseases, 2020, 70, 1900-1906.	5.8	61
22	A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. International Journal of Drug Policy, 2020, 76, 102633.	3.3	17
23	Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure. International Journal of Drug Policy, 2020, 75, 102596.	3.3	6
24	Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model. Journal of Viral Hepatitis, 2020, 27, 526-536.	2.0	9
25	Ending malnutrition in all its forms requires scaling up proven nutrition interventions and much more: a 129-country analysis. BMC Medicine, 2020, 18, 356.	5.5	29
26	A model of the economic benefits of global hepatitis C elimination: an investment case. The Lancet Gastroenterology and Hepatology, 2020, 5, 940-947.	8.1	26
27	Global hepatitis C elimination: an investment framework. The Lancet Gastroenterology and Hepatology, 2020, 5, 927-939.	8.1	28
28	Impacts of COVID-19 on childhood malnutrition and nutrition-related mortality. Lancet, The, 2020, 396, 519-521.	13.7	296
29	Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study. The Lancet Global Health, 2020, 8, e931-e941.	6.3	19
30	Authorsâ€™ response to Letter to the Editor: â€Colombian experience in the management of hepatitis Câ€™. Liver International, 2020, 40, 3142-3143.	3.9	0
31	Measuring hepatitis C virus elimination as a public health threat: Beyond global targets. Journal of Viral Hepatitis, 2020, 27, 770-773.	2.0	4
32	Australia needs to increase testing to achieve hepatitis C elimination. Medical Journal of Australia, 2020, 212, 365-370.	1.7	43
33	Blood donation amongst people who inject drugs in Australia: research supporting policy change. Vox Sanguinis, 2020, 115, 162-170.	1.5	4
34	Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection. Scientific Reports, 2020, 10, 1459.	3.3	7
35	Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study. Harm Reduction Journal, 2020, 17, 14.	3.2	51
36	Modelling the impact of migrants on the success of the HIV care and treatment program in Botswana. PLoS ONE, 2020, 15, e0226422.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30. <i>The Lancet Global Health</i> , 2019, 7, e1180-e1188.	6.3	58
38	Estimating the syphilis epidemic among gay, bisexual and other men who have sex with men in Australia following changes in HIV care and prevention. <i>Sexual Health</i> , 2019, 16, 254-262.	0.9	4
39	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. <i>Liver International</i> , 2019, 39, 1818-1836.	3.9	44
40	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. <i>BMC Medicine</i> , 2019, 17, 175.	5.5	17
41	Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. <i>Journal of Hepatology</i> , 2019, 70, 839-846.	3.7	80
42	Treatment access is only the first step to hepatitis C elimination: experience of universal antiviral treatment access in Australia. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1223-1229.	3.7	34
43	Profiling <i>Mycobacterium tuberculosis</i> transmission and the resulting disease burden in the five highest tuberculosis burden countries. <i>BMC Medicine</i> , 2019, 17, 208.	5.5	20
44	Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1089-1098.	2.0	26
45	Achieving 90-90-90 Human Immunodeficiency Virus (HIV) Targets Will Not Be Enough to Achieve the HIV Incidence Reduction Target in Australia. <i>Clinical Infectious Diseases</i> , 2018, 66, 1019-1023.	5.8	28
46	Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. <i>Journal of the International AIDS Society</i> , 2018, 21, e25059.	3.0	21
47	Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020. <i>Journal of Hepatology</i> , 2018, 68, 932-939.	3.7	53
48	The pitfalls of prevalence estimation: the case of regular and dependent methamphetamine use in Australia. <i>Addiction Research and Theory</i> , 2018, 26, 439-446.	1.9	3
49	Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond. <i>Journal of Hepatology</i> , 2018, 68, 383-385.	3.7	8
50	Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1472-1480.	2.0	27
51	Determining the effective dose of street-level heroin: A new way to consider fluctuations in heroin purity, mass and potential contribution to overdose. <i>Forensic Science International</i> , 2018, 290, 219-226.	2.2	11
52	Optima Nutrition: an allocative efficiency tool to reduce childhood stunting by better targeting of nutrition-related interventions. <i>BMC Public Health</i> , 2018, 18, 384.	2.9	24
53	Analysis of time of drug use according to needle and syringe program operating hours in Melbourne, Australia: Effects on individual-level needle and syringe coverage. <i>Drug and Alcohol Dependence</i> , 2018, 191, 259-265.	3.2	4
54	Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. <i>The Lancet Global Health</i> , 2018, 6, e659-e667.	6.3	36

#	ARTICLE	IF	CITATIONS
55	Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access. <i>Journal of Virus Eradication</i> , 2018, 4, 108-114.	0.5	8
56	Using simulation modelling to examine the impact of venue lockout and last drink policies on drinking-related harms and costs to licensees. <i>Australian and New Zealand Journal of Public Health</i> , 2017, 41, 243-247.	1.8	3
57	Longitudinal analysis of change in individual-level needle and syringe coverage amongst a cohort of people who inject drugs in Melbourne, Australia. <i>Drug and Alcohol Dependence</i> , 2017, 176, 7-13.	3.2	12
58	Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. <i>Gut</i> , 2017, 66, 1507-1515.	12.1	119
59	Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. <i>International Journal of Drug Policy</i> , 2017, 47, 107-116.	3.3	114
60	Eliminating hepatitis C virus from HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. <i>Journal of Hepatology</i> , 2017, 66, S413.	3.7	1
61	Optimally capturing latency dynamics in models of tuberculosis transmission. <i>Epidemics</i> , 2017, 21, 39-47.	3.0	31
62	How does the use of multiple needles/syringes per injecting episode impact on the measurement of individual level needle and syringe program coverage?. <i>International Journal of Drug Policy</i> , 2017, 46, 99-106.	3.3	6
63	Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 872-882.	2.8	47
64	Longitudinal changes in psychological distress in a cohort of people who inject drugs in Melbourne, Australia. <i>Drug and Alcohol Dependence</i> , 2016, 168, 140-146.	3.2	28
65	How is methamphetamine typically purchased and used in Melbourne, Australia? Reports from a cohort of people who inject drugs. <i>Addiction Research and Theory</i> , 2016, 24, 416-425.	1.9	0
66	The effects of extended public transport operating hours and venue lockout policies on drinking-related harms in Melbourne, Australia: Results from SimDrink, an agent-based simulation model. <i>International Journal of Drug Policy</i> , 2016, 32, 44-49.	3.3	20
67	Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. <i>Virulence</i> , 2016, 7, 201-208.	4.4	16
68	SimDrink: An Agent-Based NetLogo Model of Young, Heavy Drinkers for Conducting Alcohol Policy Experiments. <i>Jasss</i> , 2016, 19, .	1.8	13
69	Patterns of drug preference and use among people who inject drugs in Melbourne, Australia. <i>Addiction Research and Theory</i> , 2015, 23, 459-468.	1.9	4
70	High-frequency drug purity and price series as tools for explaining drug trends and harms in Victoria, Australia. <i>Addiction</i> , 2015, 110, 120-128.	3.3	61
71	Understanding alcohol and other drug use during the event. <i>Drug and Alcohol Review</i> , 2014, 33, 335-337.	2.1	9
72	Heavy drinking occasions in Australia: Do context and beverage choice differ from low-risk drinking occasions?. <i>Drug and Alcohol Review</i> , 2014, 33, 354-357.	2.1	15

#	ARTICLE	IF	CITATIONS
73	Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results. <i>Harm Reduction Journal</i> , 2013, 10, 11.	3.2	82
74	An urgent need to scale-up injecting drug harm reduction services in Tanzania: Prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011. <i>International Journal of Drug Policy</i> , 2013, 24, 78-81.	3.3	38